Pfizer traded at $28.12 this Thursday October 1st, decreasing $0.40 or 1.40 percent since the previous trading session. Looking back, over the last four weeks, Pfizer lost 3.10 percent. Over the last 12 months, its price rose by 3.84 percent. Looking ahead, we forecast Pfizer to be priced at 28.05 by the end of this quarter and at 26.27 in one year, according to Trading Economics global macro models projections and analysts expectations.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The Company works across markets to develop wellness, prevention, treatments and cures. It collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. Its medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness. It sells its prescription pharmaceutical products to wholesalers, retailers, hospitals, clinics, government agencies and pharmacies. In the United States, it sells its vaccines products to the federal government, centers for disease control and prevention (CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery networks.